|
|
| (11 intermediate revisions by 2 users not shown) |
| Line 1: |
Line 1: |
| {{DISPLAYTITLE:Astrocytoma, IDH-mutant}}
| | ==Primary Author(s)*== |
| | |
| | __TOC__ |
| | |
| | ==Cancer Category/Type== |
| | |
| | Put your text here |
| | |
| | ==Cancer Sub-Classification / Subtype== |
| | |
| | Put your text here |
| | |
| | ==Definition / Description of Disease== |
| | |
| | Put your text here |
| | |
| | ==Synonyms / Terminology== |
| | |
| | Put your text here |
| | |
| | ==Epidemiology / Prevalence== |
|
| |
|
| [[CNS5:Table_of_Contents|Central Nervous System Tumours (WHO Classification, 5th ed.)]]
| | Put your text here |
|
| |
|
| {{Under Construction}}
| | ==Clinical Features== |
| ==Primary Author(s)*== | | |
| Meenakshi Mehrotra, PhD, Mount Sinai Health System, New York
| | Put your text here |
| ==WHO Classification of Disease== | | |
| | ==Sites of Involvement== |
| | |
| | Put your text here |
| | |
| | ==Morphologic Features== |
| | |
| | Put your text here |
| | |
| | ==Immunophenotype== |
| | |
| | Put your text here and/or fill in the table |
|
| |
|
| {| class="wikitable" | | {| class="wikitable sortable" |
| !Structure
| |
| !Disease
| |
| |- | | |- |
| |Book
| | ! Finding !! Marker |
| |Central Nervous System Tumours (5th ed.)
| |
| |- | | |- |
| |Category | | |Positive (universal) || EXAMPLE CD1 |
| |Gliomas, glioneuronal tumours, and neuronal tumours | |
| |- | | |- |
| |Family | | |Positive (subset) || EXAMPLE CD2 |
| |Gliomas, glioneuronal tumours, and neuronal tumours | |
| |- | | |- |
| |Type | | |Negative (universal) || EXAMPLE CD3 |
| |Adult-type diffuse gliomas | |
| |- | | |- |
| |Subtype(s) | | |Negative (subset) || EXAMPLE CD4 |
| |Astrocytoma, IDH-mutant | |
| |} | | |} |
|
| |
|
| ==Related Terminology== | | ==Chromosomal Rearrangements (Gene Fusions)== |
|
| |
|
| {| class="wikitable"
| | Put your text here and/or fill in the table |
| |+
| |
| |Acceptable
| |
| |N/A
| |
| |-
| |
| |Not Recommended
| |
| |Diffuse astrocytoma, IDH-mutant; anaplastic astrocytoma, IDH-mutant; glioblastoma, IDH-mutant; low-grade astrocytoma; lower-grade astrocytoma; high-grade astrocytoma; infiltrating astrocytoma; diffuse glioma
| |
| |}
| |
|
| |
|
| ==Gene Rearrangements==
| |
| <br />
| |
| {| class="wikitable sortable" | | {| class="wikitable sortable" |
| |- | | |- |
| !Driver Gene!!Fusion(s) and Common Partner Genes!!Molecular Pathogenesis!!Typical Chromosomal Alteration(s) | | ! Chromosomal Rearrangement !! Genes in Fusion (5’ or 3’ Segments) !! Pathogenic Derivative !! Prevalence |
| !Prevalence -Common >20%, Recurrent 5-20% or Rare <5% (Disease) | |
| !Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
| |
| !Established Clinical Significance Per Guidelines - Yes or No (Source)
| |
| !Clinical Relevance Details/Other Notes
| |
| |- | | |- |
| |''MET'' | | |EXAMPLE t(9;22)(q34;q11.2) || EXAMPLE 3'ABL1 / 5'BCR || EXAMPLE der(22) || EXAMPLE 5% |
| |''PTPRZ1::MET''
| |
| |N/A
| |
| |N/A
| |
| |Rare (~1%)
| |
| |P
| |
| |No
| |
| |MET fusions and splicing variants convergently define a subgroup of glioma sensitive to MET inhibitors<ref>{{Cite journal|last=Liu|first=Lingyu|last2=Zhang|first2=Ke-Nan|last3=Zhao|first3=Zheng|last4=Li|first4=Guanzhang|last5=Chai|first5=Rui-Chao|last6=Li|first6=Zhuoqun|last7=Liu|first7=Xing|last8=Chen|first8=Jing|last9=Jiang|first9=Tao|date=2024-05|title=MET fusions and splicing variants is a strong adverse prognostic factor in astrocytoma, isocitrate dehydrogenase mutant|url=https://pubmed.ncbi.nlm.nih.gov/37530224|journal=Brain Pathology (Zurich, Switzerland)|volume=34|issue=3|pages=e13198|doi=10.1111/bpa.13198|issn=1750-3639|pmc=11007006|pmid=37530224}}</ref><ref>{{Cite journal|last=Wong|first=Queenie Hoi-Wing|last2=Li|first2=Kay Ka-Wai|last3=Wang|first3=Wei-Wei|last4=Malta|first4=Tathiane M.|last5=Noushmehr|first5=Houtan|last6=Grabovska|first6=Yura|last7=Jones|first7=Chris|last8=Chan|first8=Aden Ka-Yin|last9=Kwan|first9=Johnny Sheung-Him|date=2021-07|title=Molecular landscape of IDH-mutant primary astrocytoma Grade IV/glioblastomas|url=https://pubmed.ncbi.nlm.nih.gov/33692446|journal=Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc|volume=34|issue=7|pages=1245–1260|doi=10.1038/s41379-021-00778-x|issn=1530-0285|pmid=33692446}}</ref>
| |
| |- | | |- |
| |''NTRK2'' | | |EXAMPLE t(8;21)(q22;q22) || EXAMPLE 5'RUNX1 / 3'RUNXT1 || EXAMPLE der(8) || EXAMPLE 5% |
| |''GOLGA1::NTRK2'' | | |} |
| |N/A | | |
| |N/A | | ==Characteristic Chromosomal Aberrations / Patterns== |
| |Rare (observed in single case report)
| | |
| |P, T | | Put your text here |
| |No
| | |
| |Single case report<ref>{{Cite journal|last=Kirishima|first=Mari|last2=Akahane|first2=Toshiaki|last3=Higa|first3=Nayuta|last4=Suzuki|first4=Shinsuke|last5=Ueno|first5=Shinichi|last6=Yonezawa|first6=Hajime|last7=Uchida|first7=Hiroyuki|last8=Hanaya|first8=Ryosuke|last9=Yoshimoto|first9=Koji|date=2022-11|title=IDH-mutant astrocytoma with an evolutional progression to CDKN2A/B homozygous deletion and NTRK fusion during recurrence: A case report|url=https://pubmed.ncbi.nlm.nih.gov/36265224|journal=Pathology, Research and Practice|volume=239|pages=154163|doi=10.1016/j.prp.2022.154163|issn=1618-0631|pmid=36265224}}</ref>
| | ==Genomic Gain/Loss/LOH== |
| | |
| | Put your text here and/or fill in the table |
| | |
| | {| class="wikitable sortable" |
| |- | | |- |
| |''NTRK2''
| | ! Chromosome Number !! Gain/Loss/Amp/LOH !! Region |
| |''CDK5RAP2::NTRK2''
| |
| |N/A
| |
| |N/A
| |
| |Rare (observed in single case report)
| |
| |P, T
| |
| |No
| |
| |Single case report<ref>{{Cite journal|last=Kirishima|first=Mari|last2=Akahane|first2=Toshiaki|last3=Higa|first3=Nayuta|last4=Suzuki|first4=Shinsuke|last5=Ueno|first5=Shinichi|last6=Yonezawa|first6=Hajime|last7=Uchida|first7=Hiroyuki|last8=Hanaya|first8=Ryosuke|last9=Yoshimoto|first9=Koji|date=2022-11|title=IDH-mutant astrocytoma with an evolutional progression to CDKN2A/B homozygous deletion and NTRK fusion during recurrence: A case report|url=https://pubmed.ncbi.nlm.nih.gov/36265224|journal=Pathology, Research and Practice|volume=239|pages=154163|doi=10.1016/j.prp.2022.154163|issn=1618-0631|pmid=36265224}}</ref>
| |
| |- | | |- |
| | | | |EXAMPLE 8 || EXAMPLE Gain || EXAMPLE chr8:0-1000000 |
| | | |
| | | |
| | | |
| |
| |
| |
| |
| |
| |
| | | |
| |- | | |- |
| | | | |EXAMPLE 7 || EXAMPLE Loss || EXAMPLE chr7:0-1000000 |
| | | | |} |
| | | | |
| | | | ==Gene Mutations (SNV/INDEL)== |
| |
| | |
| |
| | Put your text here and/or fill in the tables |
| | | | |
| | | |
| |}
| |
| ==Individual Region Genomic Gain/Loss/LOH== | |
| Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: Includes aberrations not involving gene rearrangements. Details on clinical significance such as prognosis and other important information can be provided in the notes section. Can refer to CGC workgroup tables as linked on the homepage if applicable. Please include references throughout the table. Do not delete the table.'') </span> | |
| {| class="wikitable sortable" | | {| class="wikitable sortable" |
| |- | | |- |
| !Chr #!!Gain, Loss, Amp, LOH!!Minimal Region Cytoband and/or Genomic Coordinates [Genome Build; Size]!!Relevant Gene(s) | | ! Gene !! Mutation !! Oncogene/Tumor Suppressor/Other !! Presumed Mechanism (LOF/GOF/Other; Driver/Passenger) !! Prevalence (COSMIC/TCGA/Other) |
| !Diagnostic, Prognostic, and Therapeutic Significance - D, P, T | |
| !Established Clinical Significance Per Guidelines - Yes or No (Source) | |
| !Clinical Relevance Details/Other Notes
| |
| |- | | |- |
| |9 | | | EXAMPLE TP53 || EXAMPLE R273H || EXAMPLE Tumor Suppressor || EXAMPLE LOF || EXAMPLE 20% |
| |loss
| | |} |
| |chr9:21,967,752-21,995,324
| | |
| |''CDKN2A''
| | ===Other Mutations=== |
| |P
| |
| |Yes (WHO CNS5)
| |
| |Poorer prognosis<ref>{{Cite journal|last=Yang|first=Rui Ryan|last2=Shi|first2=Zhi-Feng|last3=Zhang|first3=Zhen-Yu|last4=Chan|first4=Aden Ka-Yin|last5=Aibaidula|first5=Abudumijiti|last6=Wang|first6=Wei-Wei|last7=Kwan|first7=Johnny Sheung Him|last8=Poon|first8=Wai Sang|last9=Chen|first9=Hong|date=2020-05|title=IDH mutant lower grade (WHO Grades II/III) astrocytomas can be stratified for risk by CDKN2A, CDK4 and PDGFRA copy number alterations|url=https://pubmed.ncbi.nlm.nih.gov/31733156|journal=Brain Pathology (Zurich, Switzerland)|volume=30|issue=3|pages=541–553|doi=10.1111/bpa.12801|issn=1750-3639|pmc=8018138|pmid=31733156}}</ref>
| |
| |-
| |
| |9 | |
| |loss | |
| |chr9:22,002,903-22,009,313 | |
| |''CDKN2B''
| |
| |P
| |
| |Yes (WHO CNS5)
| |
| |Poorer prognosis<ref>{{Cite journal|last=Lee|first=Kwanghoon|last2=Kim|first2=Seong-Ik|last3=Kim|first3=Eric Eunshik|last4=Shim|first4=Yu-Mi|last5=Won|first5=Jae-Kyung|last6=Park|first6=Chul-Kee|last7=Choi|first7=Seung Hong|last8=Yun|first8=Hongseok|last9=Lee|first9=Hyunju|date=2023-04-25|title=Genomic profiles of IDH-mutant gliomas: MYCN-amplified IDH-mutant astrocytoma had the worst prognosis|url=https://pubmed.ncbi.nlm.nih.gov/37185778|journal=Scientific Reports|volume=13|issue=1|pages=6761|doi=10.1038/s41598-023-32153-y|issn=2045-2322|pmc=10130138|pmid=37185778}}</ref>
| |
| |-
| |
| |12
| |
| |amp
| |
| |chr12:57,747,727-57,756,013
| |
| |''CDK4''
| |
| |P,T
| |
| |No
| |
| |Poorer prognosis<ref>{{Cite journal|last=Yang|first=Rui Ryan|last2=Shi|first2=Zhi-Feng|last3=Zhang|first3=Zhen-Yu|last4=Chan|first4=Aden Ka-Yin|last5=Aibaidula|first5=Abudumijiti|last6=Wang|first6=Wei-Wei|last7=Kwan|first7=Johnny Sheung Him|last8=Poon|first8=Wai Sang|last9=Chen|first9=Hong|date=2020-05|title=IDH mutant lower grade (WHO Grades II/III) astrocytomas can be stratified for risk by CDKN2A, CDK4 and PDGFRA copy number alterations|url=https://pubmed.ncbi.nlm.nih.gov/31733156|journal=Brain Pathology (Zurich, Switzerland)|volume=30|issue=3|pages=541–553|doi=10.1111/bpa.12801|issn=1750-3639|pmc=8018138|pmid=31733156}}</ref>
| |
| |-
| |
| |13
| |
| |loss
| |
| |chr13:48,303,744-48,599,436
| |
| |''RB1''
| |
| |P
| |
| |No
| |
| |<ref>{{Cite journal|last=Shirahata|first=Mitsuaki|last2=Ono|first2=Takahiro|last3=Stichel|first3=Damian|last4=Schrimpf|first4=Daniel|last5=Reuss|first5=David E.|last6=Sahm|first6=Felix|last7=Koelsche|first7=Christian|last8=Wefers|first8=Annika|last9=Reinhardt|first9=Annekathrin|date=2018-07|title=Novel, improved grading system(s) for IDH-mutant astrocytic gliomas|url=https://pubmed.ncbi.nlm.nih.gov/29687258|journal=Acta Neuropathologica|volume=136|issue=1|pages=153–166|doi=10.1007/s00401-018-1849-4|issn=1432-0533|pmid=29687258}}</ref>
| |
| |-
| |
| |4
| |
| |amp
| |
| |chr4:54,229,280-54,298,245
| |
| |''PDGFRA''
| |
| |P
| |
| |No
| |
| |Poorer prognosis<ref>{{Cite journal|last=Yang|first=Rui Ryan|last2=Shi|first2=Zhi-Feng|last3=Zhang|first3=Zhen-Yu|last4=Chan|first4=Aden Ka-Yin|last5=Aibaidula|first5=Abudumijiti|last6=Wang|first6=Wei-Wei|last7=Kwan|first7=Johnny Sheung Him|last8=Poon|first8=Wai Sang|last9=Chen|first9=Hong|date=2020-05|title=IDH mutant lower grade (WHO Grades II/III) astrocytomas can be stratified for risk by CDKN2A, CDK4 and PDGFRA copy number alterations|url=https://pubmed.ncbi.nlm.nih.gov/31733156|journal=Brain Pathology (Zurich, Switzerland)|volume=30|issue=3|pages=541–553|doi=10.1111/bpa.12801|issn=1750-3639|pmc=8018138|pmid=31733156}}</ref>
| |
| |-
| |
| |2
| |
| |amp
| |
| |chr2:15,940,550-15,947,007
| |
| |''MYCN''
| |
| |P
| |
| |No
| |
| |PMID: 29687258; PMID: 37185778; poorer prognosis
| |
| |-
| |
| |7
| |
| |amp
| |
| |chr7:116,672,196-116,798,377
| |
| |''MET''
| |
| |
| |
| |No
| |
| |PMID: 31667475
| |
| |-
| |
| |10
| |
| |loss
| |
| |chr10:87863113-87971930
| |
| |''PTEN''
| |
| |P
| |
| |No
| |
| |PMID: 37185778
| |
| |-
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |-
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |-
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |}
| |
| ==Characteristic Chromosomal or Other Global Mutational Patterns==
| |
| Put your text here and fill in the table <span style="color:#0070C0">(I''nstructions: Included in this category are alterations such as hyperdiploid; gain of odd number chromosomes including typically chromosome 1, 3, 5, 7, 11, and 17; co-deletion of 1p and 19q; complex karyotypes without characteristic genetic findings; chromothripsis; microsatellite instability; homologous recombination deficiency; mutational signature pattern; etc. Details on clinical significance such as prognosis and other important information can be provided in the notes section. Please include references throughout the table. Do not delete the table.'')</span>
| |
| {| class="wikitable sortable" | | {| class="wikitable sortable" |
| |- | | |- |
| !Chromosomal Pattern | | ! Type !! Gene/Region/Other |
| !Molecular Pathogenesis | |
| !Prevalence - | |
| Common >20%, Recurrent 5-20% or Rare <5% (Disease)
| |
| !Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
| |
| !Established Clinical Significance Per Guidelines - Yes or No (Source)
| |
| !Clinical Relevance Details/Other Notes
| |
| |- | | |- |
| |<span class="blue-text">EXAMPLE:</span> | | | Concomitant Mutations || EXAMPLE IDH1 R123H |
| Co-deletion of 1p and 18q
| |
| |<span class="blue-text">EXAMPLE:</span> See chromosomal rearrangements table as this pattern is due to an unbalanced derivative translocation associated with oligodendroglioma (add reference).
| |
| |<span class="blue-text">EXAMPLE:</span> Common (Oligodendroglioma) | |
| |<span class="blue-text">EXAMPLE:</span> D, P | |
| |
| |
| |
| |
| |- | | |- |
| |<span class="blue-text">EXAMPLE:</span> | | | Secondary Mutations || EXAMPLE Trisomy 7 |
| Microsatellite instability - hypermutated
| |
| | | |
| |<span class="blue-text">EXAMPLE:</span> Common (Endometrial carcinoma) | |
| |<span class="blue-text">EXAMPLE:</span> P, T
| |
| |
| |
| |
| |
| |- | | |- |
| | | | |Mutually Exclusive || EXAMPLE EGFR Amplification |
| | | |
| |
| |
| |
| |
| |
| |
| | | |
| |} | | |} |
| ==Gene Mutations (SNV/INDEL)==
| |
| Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: This table is not meant to be an exhaustive list; please include only genes/alterations that are recurrent or common as well either disease defining and/or clinically significant. If a gene has multiple mechanisms depending on the type or site of the alteration, add multiple entries in the table. For clinical significance, denote associations with FDA-approved therapy (not an extensive list of applicable drugs) and NCCN or other national guidelines if applicable; Can also refer to CGC workgroup tables as linked on the homepage if applicable as well as any high impact papers or reviews of gene mutations in this entity. Details on clinical significance such as prognosis and other important information such as concomitant and mutually exclusive mutations can be provided in the notes section. Please include references throughout the table. Do not delete the table.'') </span>
| |
| {| class="wikitable sortable"
| |
| |-
| |
| !Gene!!Genetic Alteration!!Tumor Suppressor Gene, Oncogene, Other!!Prevalence -
| |
| Common >20%, Recurrent 5-20% or Rare <5% (Disease)
| |
| !Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
| |
| !Established Clinical Significance Per Guidelines - Yes or No (Source)
| |
| !Clinical Relevance Details/Other Notes
| |
| |-
| |
| |<span class="blue-text">EXAMPLE:</span>''EGFR''
| |
|
| |
|
| <br />
| | ==Epigenomics (Methylation)== |
| |<span class="blue-text">EXAMPLE:</span> Exon 18-21 activating mutations
| | |
| |<span class="blue-text">EXAMPLE:</span> Oncogene
| |
| |<span class="blue-text">EXAMPLE:</span> Common (lung cancer)
| |
| |<span class="blue-text">EXAMPLE:</span> T
| |
| |<span class="blue-text">EXAMPLE:</span> Yes (NCCN)
| |
| |<span class="blue-text">EXAMPLE:</span> Exons 18, 19, and 21 mutations are targetable for therapy. Exon 20 T790M variants cause resistance to first generation TKI therapy and are targetable by second and third generation TKIs (add references).
| |
| |-
| |
| |<span class="blue-text">EXAMPLE:</span> ''TP53''; Variable LOF mutations
| |
| <br />
| |
| |<span class="blue-text">EXAMPLE:</span> Variable LOF mutations
| |
| |<span class="blue-text">EXAMPLE:</span> Tumor Supressor Gene
| |
| |<span class="blue-text">EXAMPLE:</span> Common (breast cancer)
| |
| |<span class="blue-text">EXAMPLE:</span> P
| |
| |
| |
| |<span class="blue-text">EXAMPLE:</span> >90% are somatic; rare germline alterations associated with Li-Fraumeni syndrome (add reference). Denotes a poor prognosis in breast cancer.
| |
| |-
| |
| |<span class="blue-text">EXAMPLE:</span> ''BRAF''; Activating mutations
| |
| |<span class="blue-text">EXAMPLE:</span> Activating mutations
| |
| |<span class="blue-text">EXAMPLE:</span> Oncogene
| |
| |<span class="blue-text">EXAMPLE:</span> Common (melanoma)
| |
| |<span class="blue-text">EXAMPLE:</span> T
| |
| |
| |
| |
| |
| |-
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |}Note: A more extensive list of mutations can be found in [https://www.cbioportal.org/ <u>cBioportal</u>], [https://cancer.sanger.ac.uk/cosmic <u>COSMIC</u>], and/or other databases. When applicable, gene-specific pages within the CCGA site directly link to pertinent external content.
| |
| ==Epigenomic Alterations==
| |
| Put your text here | | Put your text here |
| | |
| ==Genes and Main Pathways Involved== | | ==Genes and Main Pathways Involved== |
| Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: Please include references throughout the table. Do not delete the table.)''</span> | | |
| {| class="wikitable sortable"
| | Put your text here |
| |-
| | |
| !Gene; Genetic Alteration!!Pathway!!Pathophysiologic Outcome
| | ==Diagnostic Testing Methods== |
| |-
| | |
| |<span class="blue-text">EXAMPLE:</span> ''BRAF'' and ''MAP2K1''; Activating mutations
| | Put your text here |
| |<span class="blue-text">EXAMPLE:</span> MAPK signaling
| | |
| |<span class="blue-text">EXAMPLE:</span> Increased cell growth and proliferation
| | ==Clinical Significance (Diagnosis, Prognosis and Therapeutic Implications)== |
| |-
| | |
| |<span class="blue-text">EXAMPLE:</span> ''CDKN2A''; Inactivating mutations
| | Put your text here |
| |<span class="blue-text">EXAMPLE:</span> Cell cycle regulation
| | |
| |<span class="blue-text">EXAMPLE:</span> Unregulated cell division
| |
| |-
| |
| |<span class="blue-text">EXAMPLE:</span> ''KMT2C'' and ''ARID1A''; Inactivating mutations
| |
| |<span class="blue-text">EXAMPLE:</span> Histone modification, chromatin remodeling
| |
| |<span class="blue-text">EXAMPLE:</span> Abnormal gene expression program
| |
| |-
| |
| |
| |
| |
| |
| |
| |
| |}
| |
| ==Genetic Diagnostic Testing Methods==
| |
| Put your text here <span style="color:#0070C0">(''Instructions: Include recommended testing type(s) to identify the clinically significant genetic alterations.'')</span> | |
| ==Familial Forms== | | ==Familial Forms== |
| Put your text here <span style="color:#0070C0">(''Instructions: Include associated hereditary conditions/syndromes that cause this entity or are caused by this entity.'') </span> | | |
| ==Additional Information== | | Put your text here |
| | |
| | ==Other Information== |
| | |
| Put your text here | | Put your text here |
| | |
| ==Links== | | ==Links== |
| Put a link here or anywhere appropriate in this page <span style="color:#0070C0">(''Instructions: Highlight the text to which you want to add a link in this section or elsewhere, select the "Link" icon at the top of the wiki page, and search the name of the internal page to which you want to link this text, or enter an external internet address by including the "<nowiki>http://www</nowiki>." portion.'')</span> | | |
| | Put your links here |
| | |
| ==References== | | ==References== |
| (use the "Cite" icon at the top of the page) <span style="color:#0070C0">(''Instructions: Add each reference into the text above by clicking where you want to insert the reference, selecting the “Cite” icon at the top of the wiki page, and using the “Automatic” tab option to search by PMID to select the reference to insert. If a PMID is not available, such as for a book, please use the “Cite” icon, select “Manual” and then “Basic Form”, and include the entire reference. To insert the same reference again later in the page, select the “Cite” icon and “Re-use” to find the reference; DO NOT insert the same reference twice using the “Automatic” tab as it will be treated as two separate references. The reference list in this section will be automatically generated and sorted''</span><span style="color:#0070C0">''.''</span><span style="color:#0070C0">)</span>
| |
| ==Notes==
| |
| <nowiki>*</nowiki>Primary authors will typically be those that initially create and complete the content of a page. If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the [[Leadership|''<u>Associate Editor</u>'']] or other CCGA representative. When pages have a major update, the new author will be acknowledged at the beginning of the page, and those who contributed previously will be acknowledged below as a prior author.
| |
|
| |
|
| Prior Author(s):
| | === EXAMPLE Book === |
| <nowiki>*</nowiki>''Citation of this Page'': “Astrocytoma, IDH-mutant”. Compendium of Cancer Genome Aberrations (CCGA), Cancer Genomics Consortium (CGC), updated {{REVISIONMONTH}}/{{REVISIONDAY}}/{{REVISIONYEAR}}, <nowiki>https://ccga.io/index.php/CNS5:Astrocytoma, IDH-mutant</nowiki>.
| | #Arber DA, et al., (2008). Acute myeloid leukaemia with recurrent genetic abnormalities, in World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4thedition.Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, Editors. IARC Press: Lyon, France, p117-118. |
| [[Category:CNS5]]
| | |
| [[Category:DISEASE]]
| | === EXAMPLE Journal Article === |
| [[Category:Diseases A]]
| | #Li Y, et al., (2001). Fusion of two novel genes, RBM15 and MKL1, in the t(1;22)(p13;q13) of acute megakaryoblastic leukemia. Nat Genet 28:220-221, PMID 11431691. |
| | |
| | == Notes == |
| | <nowiki>*</nowiki>Primary authors will typically be those that initially create and complete the content of a page. If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the CCGA coordinators (contact information provided on the homepage). Additional global feedback or concerns are also welcome. |